Sustained Release Excipients Market Intelligence Report Covers Trends, Segments And Regional Growth

The sustained release excipients market has been demonstrating significant growth, driven by advances in pharmaceutical formulations and increasing demand for controlled drug delivery systems. This sector is shaping the future of medication administration by enabling more efficient and patient-friendly treatment options. Let's explore the current market size, driving factors, key players, trends, and important segments that define this market's trajectory.

Sustained Release Excipients Market Size and Growth Expectations
The market for sustained release excipients has experienced robust expansion in recent years. It is projected to increase from $1.51 billion in 2025 to $1.63 billion in 2026, registering a compound annual growth rate (CAGR) of 8.2%. This historical growth is largely attributed to the rising prevalence of chronic diseases, greater adoption of modified release tablets, innovations in polymer chemistry, the growth of generic drug manufacturing, and regulatory endorsement of sustained release drug formulations.

Download a free sample of the sustained release excipients market report:
https://thebusinessresearchcompany.com/sample_request?id=70041045&type=smp&name=Sustained%20Release%20Excipients%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Looking ahead, the market is forecasted to continue its strong upward trend, reaching a valuation of $2.3 billion by 2030 with an anticipated CAGR of 8.9%. This future growth is expected to be driven by factors such as increasing demand for long-acting injectable drugs, expansion in biologics and specialty pharmaceuticals, rising investments in drug delivery research and development, focus on patient-centered formulations, and growing pharmaceutical production in emerging economies. Emerging trends include heightened interest in controlled drug delivery, expanded use of polymers in sustained release products, wider acceptance of oral sustained release dosage forms, advances in microencapsulation and coacervation technologies, and a strong emphasis on improving patient compliance through reduced dosing frequency.

Key Drivers Behind Growth in the Sustained Release Excipients Market
One of the main growth catalysts in this market is the increasing prevalence of chronic illnesses which require prolonged medication regimens. Sustained release excipients help improve therapeutic outcomes by ensuring consistent drug delivery over extended periods.

View the full sustained release excipients market report:
https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Another significant driver is the ongoing innovation in drug formulation technologies, including polymer chemistry advancements that enable more precise control over drug release profiles. Additionally, the regulatory acceptance of sustained release formulations has encouraged manufacturers to adopt these excipients more widely.

Prominent Players Influencing the Sustained Release Excipients Market
Several leading companies dominate the sustained release excipients industry, including BASF SE, Ashland Global Holdings Inc, Colorcon Inc, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, Roquette Freres, Shin Etsu Chemical Co Ltd, JRS Pharma GmbH Co KG, SPI Pharma Inc, Croda International Plc, Lonza Group AG, Chemische Fabrik Budenheim KG, Asahi Kasei Corporation, DuPont de Nemours Inc, Dow Chemical Company, Eastman Chemical Company, Gattefosse SAS, Balchem Corporation, Associated British Foods plc, Ransom Naturals Ltd, and Cellulose Solutions Private Limited.

Significant Market Developments in 2024
In March 2024, Roquette, a pharmaceutical excipient provider based in France, completed the acquisition of IFF Pharma Solutions, a US-based company specializing in sustained-release excipients. This strategic move aims to bolster Roquette's market position by enhancing its portfolio of specialized ingredients that regulate the release rates of active pharmaceutical ingredients (APIs) in drug formulations.

Advancements and Emerging Opportunities in Sustained Release Excipients
Market leaders are focusing on developing multifunctional polymer platforms to enhance drug formulation efficiency, shorten delivery times, and support a variety of controlled-release profiles. These polymer platforms enable immediate, delayed, and sustained drug release while being compatible with advanced formulation methods such as hot melt extrusion and solubility-enhancing spray drying techniques.

For example, in September 2024, Evonik, a German chemical company, inaugurated a new spray drying plant at its Darmstadt location dedicated to producing EUDRAGIT polymers. This facility boosts production capacity, cuts down delivery times, and integrates smoothly with existing manufacturing operations. It operates using green electricity and steam generated from local waste incineration, reducing CO2 emissions by over 1,000 tons annually. The plant complies with IPEC-GMP pharmaceutical standards and is directly linked to aqueous dispersion production, which streamlines the supply chain and minimizes transportation. The polymers produced support a broad range of drug release profiles, reinforcing Evonik's role as a global leader in oral drug delivery solutions and accelerating pharmaceutical innovation.

Breakdown of Key Segments Shaping the Sustained Release Excipients Market
This market is categorized into multiple segments:

1) By Product Type: Gelatin, Polymers, Minerals, and Chitosan
2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, and Other Routes
3) By Technology: Targeted Delivery, Microencapsulation, Wurster Technique, Transdermal, Implants, and Coacervation

Subdivisions within these categories include:
- Gelatin segmented into Type A and Type B Gelatin
- Polymers divided into Natural and Synthetic Polymers
- Minerals including Calcium Compounds, Magnesium Compounds, and other mineral excipients
- Chitosan classified as Low Molecular Weight and High Molecular Weight

Regional and technological diversity within these segments supports the development of personalized and efficient sustained release medication options across various treatment modalities.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.